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INTRODUCTION
There is a clinical need for improved non-invasive
means to diagnose and predict the course of auto-
immune thrombocytopenia (ITP). As the cause of ele-
vated platelet-associated IgG (PA-IgG) in multiple
thrombocytopenic states is still unclear, such
tests have been considered unnecessary and even
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SUMMARY
Recent evidence suggests that platelet-associated glycoprotein-speciﬁc
(GP) antibodies represent true positive autoantibodies and can there-
fore be taken as the gold standard. Earlier tests, which aimed at
detecting platelet-associated IgG (PA-IgG), might have been hampered,
e.g. by the variation of platelet size in thrombocytopenic patients. In
this study, 206 samples with increased PA-IgG from consecutive
thrombocytopenic patients were tested further for GP-speciﬁc antibod-
ies with a monoclonal antibody immobilized platelet antigen test
(MAIPA) using a combination of a GP IIbIIIa-speciﬁc and a GP IbIX-
speciﬁc antibody for immobilization or, in a separate assay, GP
V-speciﬁc antibody. Mean platelet size was recorded as forward scatter
(FSC) of platelets in ﬂow cytometrica n a l y s i so fP A - I g G .G P - s p e c i ﬁ c
antibodies were detected in 49 (24%) of the 206 patient samples. Their
presence correlated well with increased PA-IgG (R ¼ 0.769). The mean
platelet size and mean ﬂuorescence intensity (MFI) of PA-IgG were
both signiﬁcantly increased in patients compared with healthy controls
(n ¼ 112; P < 0.0001). Notably, PA-IgG was associated with platelet
size within the platelet population of both healthy controls and patients
(R ¼ 0.999). Further, the probability of GP IIbIIIa and/or IbIX and GP
V-speciﬁc PA-IgG tended to increase with the mean platelet size of the
patients (P ¼ 0.045). In conclusion, large platelets bound more IgG
than platelets of normal size, which may explain at least in part the
reported low speciﬁcity of total PA-IgG measurement. As the PA-IgG
displays low speciﬁcity compared with the gold standard, its use as such
may be abandoned and replaced by tests for platelet-associated
GP-speciﬁc autoantibodies.
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(Mueller-Eckhardt et al., 1980; George et al., 1996). A
part of the problem could reﬂect the variation of
platelet size in thrombocytopenic patients (Illes et al.,
1987; Holme et al., 1988b; Jackson & Carter, 1993).
Forward scatter signal distributions of platelets
(FSC) in ﬂow cytometry have been presented as fairly
comparable with platelet size distributions as deter-
mined by hematology cell counter (Holme et al.,
1988b). Although ﬂow cytometry has been applied for
the detection of PA-IgG (Holme et al., 1988a; Holme
et al., 1988b; Kokawa, Nomura & Yasunaga, 1991;
Ault & Mitchell, 1994; Leytin et al., 1996; Hagenstrom
et al., 2000), little attention has been paid to platelet
size in the same measurement (Holme et al., 1988b).
Glycoprotein (GP)-speciﬁcity of platelet-associated
autoantibodies can be determined by antigen-speciﬁc
assays, such as monoclonal antibody-speciﬁc immobil-
ization of platelet antigen assay (MAIPA; Kiefel et al.,
1987), and radioactive immunobead assay (McMillan
et al., 1987). Tomer and collaborators reported that
the presence of ITP was highly probable (>90%) if the
antigen-speciﬁc assay was positive (Tomer, Koziol &
McMillan, 2005). However, a negative assay does not
rule out the diagnosis (McMillan, 1995; Tomer, Koziol
& McMillan, 2005). Antigen-speciﬁc assays may be
also useful in other thrombocytopenic patients than
ITP (McMillan, 2005) and may be taken as the gold
standard of platelet autoantibody assays.
The aims of the present study were (i) to character-
ize the normal reference ranges for PA-IgG and plate-
let size of a PA-IgG assay where results were obtained
by ﬂow cytometry, (ii) to study the correlation of
platelet size with PA-IgG and (iii) to detect GP-speciﬁc
autoantibodies with an independent assay in the
patients with increased PA-IgG and (iv) to study whe-
ther the GP-speciﬁc autoantibodies were present more
frequently in patients with platelets larger than nor-
mal.
MATERIALS AND METHODS
Patient samples
Samples from 854 thrombocytopenic patients were
screened for PA-IgG. 206 samples with increased PA-
IgG [mean ﬂuorescence intensity (MFI) cut-off value
above 300 as determined by mean+2s of healthy con-
trols] formed the study population tested for GP-speci-
ﬁc autoantibodies (Figure 1). Amongst other data, the
lowest (nadir) and the actual platelet count were
requested in the sample referrals. Although most
referrals included suspected ITP, the clinical condition
was multifactorial in most of cases. Thus, these
patients were background patient material of this
study. The focus, however, was on platelet size and
GP-speciﬁc PA-IgG.
Healthy controls
Samples from 112 controls were obtained from
healthy volunteer blood donors and handled similarly
Figure 1. Distribution of consequent patient samples according to screening for platelet-associated IgG (PA-IgG) and
results of further determination of glycoprotein (GP)-speciﬁcity of PA-IgG.
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each run (see Controls).
Measurement of PA-IgG
Venous blood was collected in three 10 ml EDTA
tubes (Venoject, Terumo 288267 or Vacutainer, Bec-
ton Dickinson 368457; Becton Dickinson, Franklin
Lakes, NJ, USA), which were transported at room
temperature. The samples were handled within 24 h.
PA-IgG analysis was performed as a screening
method as described earlier (dem Borne et al., 1978;
Ault & Mitchell, 1994; Joutsi & Kekomaki, 1997). The
analyses were performed using a FACScan ﬂow cyt-
ometer and Cell Quest program, version 3.1f (Becton
Dickinson, Mountain View, CA, USA). To enable ana-
lysis of thrombocytopenic samples, no more than
5000 cells were investigated from each sample. If
necessary, the gate was adjusted daily according to
the healthy control sample. The mean FSC and MFI
of PA-IgG were recorded.
To analyze if platelets of different size in a single
sample had different amounts of PA-IgG, the platelet
scatter in FSC/SSC plot was divided into ﬁve consecu-
tive gates (R1–R5). Altogether, 54 randomly selected
samples were analyzed for PA-IgG using these gates
(samples from patients with large, n ¼ 27, with nor-
mal, n ¼ 22, and with small platelets, n ¼ 5). R3 was
set to include 50% of events and both R2 and R4
20%. R1 and R5 were set to include events outside
R2–R4 (Figure 2).
Controls
The preanalytical factors were covered by the use of
controls, which were handled strictly in the same way
as patient samples to minimize the inﬂuence of, e.g.
whole blood storage prior to preparation (Hagenstrom
et al., 2000), EDTA (Lucas & Holburn, 1987; Kuijpers
et al., 1992; O’Malley et al., 1996; Nishioka et al.,
2002), and ﬁxation with formaldehyde (De Caterina
et al., 2002). The inﬂuence of preventive maintenance
of ﬂow cytometry on the precision of the assay was
minimized by analyzing the controls and at least 10
patient samples before and after maintenance. The
parameter settings were adjusted if there was a sys-
tematic difference of >3% (three times during
5 years).
A sample from a random healthy donor was used as
a control to check all steps of analysis, and to follow the
stability of the cut-off level. A strong positive control
was used to monitor the linearity and stability of the
measurement at high levels of PA-IgG. It controlled the
analysis from the step of labeling of the platelets to
the measurement. The control was prepared by incuba-
ting a pooled platelet preparation from six blood group
O donors with 1 : 2 diluted serum containing strong
anti-HPA-1a antibodies. The dilution level of anti-HPA-
1a serum was chosen so that the PA-IgG result of the
control would be as high as possible but still within
the linear region of the ﬂuorescence (data not shown).
The same batch was used for up to 1 year.
A cut-off (positive) control was used to monitor
the linearity and stability of the measurement near
the positive (cut-off) level. The control was prepared
by incubating a pooled platelet preparation from six
blood group O donors with 1 : 64 dilution of the same
serum as for the strong positive control. The same
batch was used for up to 1 year. A new batch of all
controls in the same series was compared to the previ-
ous batch for three to ﬁve times to establish new tar-
get values. Only one control was changed at a time.
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Figure 2. Platelet populations gated according to
platelet size (forward scatter, FSC). Five regions of
platelets from a healthy control sample in FSC/SSC
(side scatter) dot plot were set: R3 to include 50% of
events, both R2 and R4 20%, and R1 and R5 events
left outside R2–R4.
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GP-speciﬁc PA-IgG was measured by direct MAIPA as
originally described (Kiefel et al., 1987) and recently
by us (Joutsi-Korhonen et al., 2001). For measure-
ment of GP IIbIIIa and/or IbIX speciﬁc antibodies,
25 ll of platelet suspension (1000 · 10
9 cells/l) was
incubated for 30 min at 37  C with 0.2 lg of two
monoclonal antibodies in a single tube, one speciﬁc
for the GP Iba (AP1) and the other speciﬁc for the GP
IIb-IIIa (AP2; both generous gifts from Doctors Ku-
nicki and Montgomery, Blood Center of Southeastern
Wisconsin, Milwaukee, WI, USA). In the separate
measurement of GP V-speciﬁc antibodies, 80 llo f
thawed platelet suspension (1000 · 10
9 cells/l) was
incubated with 0.2 lg of monoclonal antibody speciﬁc
for GP V (SW16, CLB, Netherlands). The secondary
antibody was an afﬁnity-puriﬁed goat antihuman IgG,
Fc-speciﬁc, peroxidase labeled (Jackson 109-035-098;
Suffolk, UK). The absorbances were measured at
492 nm with a spectrophotometer applying special
software (Multiscan EX, Thermo Electron Corporation,
Vantaa, Finland). To enable inter- and intralaboratory
comparisons, the absorbance values of patient samples
were divided by the absorbance of a negative control
in each test series to get the ratio value, as recom-
mended in the literature (Berchtold et al., 1997). A
sample was considered to have increased GP-speciﬁc
PA-IgG when the ratio was  2.0.
Controls for the MAIPA
Platelets with GP IIbIIIa-speciﬁc PA-IgG (anti-HPA-1a
sensitized platelets) and platelets with increased GP
V-speciﬁc PA-IgG (Joutsi-Korhonen et al., 2001) were
used as controls to monitor the measuring range of
the assay.
Comparability of platelet size measurements by two cell
counters and ﬂow cytometry
In preliminary experiments, the platelet count and
mean platelet volume (MPV) of 52 consecutive patient
samples were determined both with an electric cell
counter applying the impedance method (Medonic,
Solna, Sweden) and another cell counter applying the
hydrodynamic focusing method (Sysmex XT-2000i,
Sysmex Corporation, Kobe, Japan). The results corre-
lated well (n ¼ 52; R ¼ 0.954, data not shown). The
impedance method spared the samples of thrombocy-
topenic patients. Platelet size (MPV, range 10–16 ﬂ;
impedance method) correlated well with the mean of
FSC (range 268–552) obtained by ﬂow cytometry
(n ¼ 32; R ¼ 0.834; data not shown). The reference
range of healthy control samples (n ¼ 40) was 7–10 ﬂ.
Quality assurance of the methods
Westgard multirule quality control rules 13s,2 2s, and
41s were applied to control results to detect random
and systematic errors (Westgard et al., 1981).
Precision, cut-off values and reference intervals of the
PA-IgG assay
The precision of the PA-IgG method measured as intra-
assay and inter-assay repeatability of control samples
varied at low level from 1.9% to 4.5% and at high level
from 0.4% to 1.6% (Table 1). The intra-assay and
inter-assay repeatability of the GP IIbIIIa and/or IbIX-
and GP V-speciﬁc determinations of PA-IgG were 5.8%
and 12%, which is typical of ELISA methods.
Long-term precision was evaluated by monitoring
the annual cut-off value of PA-IgG, which was calcu-
lated from the results of donor samples (mean+2s;
300–309), and monitoring the stability of the refer-
ence interval for the FSC of the healthy control popu-
lation (mean ± 2s; 310–376; Table 2).
The reference intervals of the FSC and cut-off-val-
ues of PA-IgG did not differ statistically signiﬁcantly
during the ﬁve consecutive years (P > 0.999, Table 2).
The results indicate good long-term stability. Patient
means were analyzed to detect any long-term drift in
PA-IgG measurement (Bull et al., 1974; Table 2).
Statistics
Microsoft
  Excel 2003 (Microsoft Corporation) and
StatsDirect (version 1.8.10) were used for statistical
analysis (mean, standard deviation, SD, coefﬁcient of
variation, CV, and skewness of distribution). The cor-
relations between methods, R
2, and the signiﬁcance of
R were calculated with multiple linear regression
tests. The Mann–Whitney test was used to calculate
P-values. The j
2-test was used to study the signiﬁ-
cance of differences in GP IIbIIIa and/or IbIX and GP
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below 0.05 were considered statistically signiﬁcant.
RESULTS
Platelet size (FSC) related to PA-IgG
In all screened patients, there was more PA-IgG in
samples of platelets from patients than of platelets
from healthy controls (316 ± 69.6 and 219 ± 40.7,
respectively; P < 0.0001; Figure 3a).
The mean FSC of the patient population was signi-
ﬁcantly higher than that of the healthy control popu-
lation (369 ± 30 and 342 ± 17, respectively;
P < 0.0001; Figure 3b). Thirty-four percent of patient
samples were on the upper side of the reference inter-
val (FSC > 376) and 0.6% below (FSC < 306).
Of the 854 patient samples, 295 had increased
PA-IgG (MFI > 300; Figure 1). PA-IgG was directly
associated with platelet size within gated platelet pop-
ulations of both control and patient samples (Figure 4;
R ¼ 0.999).
GP-speciﬁcity of PA-IgG
GP IIbIIIa and/or IbIX-speciﬁc PA-IgG was detectable
in 44 samples (21%) and GP V-speciﬁc PA-IgG in 25
of 206 samples (12%). Only low level of GP V-speciﬁc
PA-IgG was found in ﬁve samples without GP IIbIIIa
and/or IbIX-speciﬁcity. GP IIbIIIa and/or IbIX-speciﬁc
PA-IgG was directly associated with GP V-speciﬁc PA-
IgG (R ¼ 0.374, data not shown). Altogether GP
IIbIIIa and/or IbIX and/or GP V-speciﬁc PA-IgG were
detected in 49 of 206 samples (24%; Figure 1).
Table 2. Reference intervals of FSC and cut-off values of platelet-associated IgG (PA-IgG)
Year n
Healthy controls
n
Patients
FSC PA-IgG (MFI) FSC PA-IgG (MFI)
Mean ± 2SD* Mean + 2SD† Mean SD Mean SD
1 108 318–385 302 1012 389 29.9 291 98.5
2 102 320–386 309 965 374 27.5 290 75.3
3 111 306–366 301 866 377 28.0 294 99.2
4 108 304–387 309 886 374 34.7 333 78.6
5 112 309–376 300 854 369 30.0 316 69.6
*Annual reference intervals (mean ± 2SD) for forward scatter signal distributions of platelets (FSC).
†95% cut-off values for PA-IgG (mean+2SD) from healthy control results. Annual control means did not differ statisti-
cally from each other (P > 0.999) whereas patient means were higher than the control means (P < 0.0001).
Table 1. Precision of platelet-associated IgG (PA-IgG) and glycoprotein (GP)-speciﬁc assays
Control level
PA-IgG assay GP-speciﬁc assays
Intra-assay CV Inter-assay CV Intra-assay CV Inter-assay CV
FSC PA-IgG (MFI) FSC PA-IgG (MFI) GPIIbllla/IblX GPV GPIIbllla/IblX GPV
Low 1.9 2.3 3.4 4.5 2.5 2.1 5.3 4.5
High 0.4 0.7 0.6 1.6 5.8 5.1 12.3 11.5
Values are expressed as precentage (%).
FSC, forward scatter; PA-IgG, platelet associated IgG; MFI, mean ﬂuorescence intensity; GP IIbIIIa and/or IbIX and GP
V, glycoprotein speciﬁcity of autoantibodies.
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GP IIbIIIa and/or IbIX, and/or GP V-speciﬁc PA-IgG
(Figure 5a, R ¼ 0.769). When compared with healthy
control samples, the cumulative frequency distribu-
tions of FSC were signiﬁcantly higher in patients
where GP-speciﬁc PA-IgG could be studied
(P < 0.0001). However, platelets were only slightly
larger in patients with GP-speciﬁc PA-IgG than in
patients without (n ¼ 49 and n ¼ 157, P ¼ 0.048;
Figure 5b).
GP IIbIIIa and/or IbIX, and/or GP V-speciﬁc PA-IgG
were more frequently detected in patient samples
with larger platelets than in samples with normal
sized platelets (P ¼ 0.045). Thirty two percent of
patients with larger platelets had GP-speciﬁc antibod-
ies, compared with 19% of patients with platelets of
normal size.
Platelet autoantibodies and platelet count
The historical platelet nadir recorded in the referrals
of the 27 of 44 patients with GP-speciﬁc PA-IgG dis-
played negative correlation with the level of GP IIbIIIa
and/or IbIX-speciﬁc PA-IgG (R ¼ )0.544, data not
shown).
DISCUSSION
Monitoring measures of platelet size, such as mean
platelet volume (Illes et al., 1987; George et al., 1996;
Rajantie et al., 2004), size deviation width (PDW) and
platelet large cell ratio (P-LCR; Kaito et al., 2005), as
well as proportion of immature platelet fraction
(Briggs et al., 2004) have been suggested to aid in the
diagnosis of thrombocytopenia.
Until now, relatively little attention has been paid
to evaluating of platelet size in association with plate-
let antibody studies (Holme et al., 1988b; Kokawa,
Nomura & Yasunaga, 1991). In this study, platelet size
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Figure 3. Cumulative frequency distributions of platelet-associated IgG (PA-IgG; a) and forward scatter signal distri-
bution of platelets (FSC; b) in healthy controls (n ¼ 112) and in all screened patients (n ¼ 854; P < 0.0001).
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patients than in healthy controls on the analysis of
PA-IgG. Furthermore, PA-IgG correlated directly with
the FSC within platelet populations of both healthy
donors and patients. Thus, the larger the platelet was,
the more IgG was bound by the cell. As the PA-IgG is
indeed related to FSC, it suggests the possibility of
estimating the amount of IgG bound per unit platelet
surface area (Leytin et al., 1996). The diagnostic value
of platelet size distributions of a sample should be tes-
ted in detection of autoantibodies in patients with
deﬁnitive ITP and other thrombocytopenic states.
The reference ranges of both FSC and PA-IgG in
PA-IgG assay remained within narrow limits. To obtain
reproducible results for this analysis, it was necessary
to perform laboratory measurements in a strictly con-
trolled way. In this context, rules originally developed
for quantitative measurements were applied and
seemed to work well (Bull et al., 1974; Westgard et al.,
1981; Cembrowski & Westgard, 1985; Lott et al.,
1996). This was especially important because interna-
tional quality assurance for the measurement of plate-
let autoantibodies is still not available.
In the present study, PA-IgG showed strong direct
association with GP IIbIIIa and/or IbIX and/or GP
V-speciﬁc PA-IgG, which was taken as the gold stand-
ard for platelet autoantibody assays. GP-speciﬁc auto-
antibodies have been detected in varying proportions
in autoimmune thrombocytopenia (McMillan, Wang
& Tani, 2003). Brighton et al. (1996) reported a posi-
tivity rate of 49% in 66 ITP-patients and in 6/15
patients with secondary immune TP. Also, 22% of
patients with initial diagnosis of non-immune TP were
reported positive. McMillan, Wang & Tani (2003) stu-
died 282 chronic ITP patients, and 55.4% of them had
GP IIbIIIa and/or IbIX-speciﬁc PA-IgG. In the present
study, GP IIbIIIa/IbIX and/or GP V-speciﬁc autoanti-
bodies were observed in a quarter of patients who
had sufﬁcient platelets to measure GP-speciﬁcity. The
low sensitivities of GP-speciﬁc PA-IgG may vary
according to the selection of the patient population.
In a strictly diagnosed ITP with extensive exclusion of
other causes of thrombocytopenia, higher sensitivity
of GP-speciﬁc antibody assay would be expected
(McMillan, Wang & Tani, 2003). Also, the selection of
the cut-off value has an inﬂuence on the assay sensi-
tivity. The proportion of patients with GP-speciﬁc
antibodies would have been larger if the cut-off value
of +3s (MFI 340) had been used instead of +2s (MFI
300) for PA-IgG. Although GP-speciﬁc antibodies were
not tested in the patient population without PA-IgG,
the probability of ﬁnding GP-speciﬁc autoantibodies in
such patients would have remained low. The previous
results from the same laboratory indicated that when
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Figure 5. The association of GP IIbIIIa/IbIX-speciﬁc antibodies and PA-IgG (n ¼ 49; ( ). In addition, low level of GP
V-speciﬁc PA-IgG was found in ﬁve samples without GP IIbIIIa and/or IbIX-speciﬁcity (u; a). Cumulative
frequency distributions of FSC were signiﬁcantly higher in patients where GP-speciﬁc PA-IgG could be studied
(n ¼ 49; P < 0.0001). Platelets were only slightly larger in patients with GP-speciﬁc PA-IgG than in patients
without (n ¼ 49 and 157, respectively; P ¼ 0.048; b).
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only 2% of patients without increased PA-IgG had
slightly increased GP-speciﬁc antibodies (Joutsi &
Kekomaki, 1997). A suboptimal combination of
monoclonal antibodies applied in the detection of GP-
speciﬁcity might also have contributed to the propor-
tion of samples with GP-speciﬁc antibodies.
In the present study, the frequency of GP IIbIIIa
and/or IbIX, and/or GP V-speciﬁc PA-IgG was statisti-
cally higher in patients with larger platelets although
the platelets were still within the reference range
(FSC). Interestingly, Kokawa, Nomura & Yasunaga
(1991) reported larger platelet volume in ITP patients
without GP IIbIIIa-speciﬁc antibodies than in those
with GP IIbIIIa-speciﬁc antibodies. Their separate ana-
lyses of GP IIbIIIa and IbIX speciﬁc antibodies may
explain the disparity in results.
Glycoprotein IIbIIIa has been shown to carry the
most common target antigens in ITP (Beardsley et al.,
1984; McMillan et al., 1987; Kekomaki et al., 1991). In
addition, GP IbIX is a prominent target antigen (Kiefel
et al., 1991). In this study, GP IIbIIIa-speciﬁc PA-IgG
was measured together with GP IbIX PA-IgG. The signi-
ﬁcance of GPV-speciﬁc PA-IgG remained unclear. Inter-
estingly, antigen-speciﬁc assays have been reported to
demonstrate high speciﬁcity in the diagnosis of ITP
(McMillan, 2005; Tomer, Koziol & McMillan, 2005).
In conclusion, it was possible to achieve reproduci-
ble results in the PA-IgG and GP-speciﬁc PA-IgG
assays. The high frequency of increased PA-IgG by
ﬂow cytometry suggested low speciﬁcity as GP-speciﬁ-
city of the antibodies could be demonstrated relatively
rarely. Thus every attempt should be made to spare
all platelets of the sample for direct measurement of
GP-speciﬁc PA-IgG. Even if platelet size was measured
separately by a hematology analyzer, the results
should be analyzed together with the platelet anti-
body assay. When interpreting the size of platelets,
other disorders in addition to ITP that can cause
macrothrombocytopenia with shortened platelet survi-
val time have to be kept in mind, e.g. Bernard-Soulier
disease (Koskela et al., 1999). Prospective studies are
indicated to test the diagnostic and predictive value of
tests for GP-speciﬁc antibodies and platelet size in TP
patients.
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